标杆管理
公制(单位)
医学
抗生素
抗菌管理
排名(信息检索)
抗生素管理
消费(社会学)
人工智能
计算机科学
运营管理
业务
抗生素耐药性
营销
工程类
社会学
微生物学
生物
社会科学
作者
Satoshi Kakiuchi,Daniel J. Livorsi,Eli N. Perencevich,Daniel J. Diekema,Dilek İnce,Kunatum Prasidthrathsint,Patrick Kinn,Kelly M Percival,Brett H. Heintz,Michihiko Goto
摘要
Abstract Background Days of therapy (DOT), the most widely used benchmarking metric for antibiotic consumption, may not fully measure stewardship efforts to promote use of narrow-spectrum agents and may inadvertently discourage the use of combination regimens when single-agent alternatives have greater adverse effects. To overcome the limitations of DOT, we developed a novel metric, days of antibiotic spectrum coverage (DASC), and compared hospital performances using this novel metric with DOT. Methods We evaluated 77 antibiotics in 16 categories of antibacterial activity to develop our spectrum scoring system. DASC was then calculated as cumulative daily antibiotic spectrum coverage (ASC) scores. To compare hospital benchmarking using DOT and DASC, we conducted a retrospective cohort study of adult patients admitted to acute care units within the Veterans Health Administration system in 2018. Antibiotic administration data were aggregated to calculate each hospital’s DOT and DASC per 1000 days present (DP) for ranking. Results The ASC score for each antibiotic ranged from 2 to 15. There was little correlation between DOT per 1000 DP and DASC per DOT, indicating that lower antibiotic consumption at a hospital does not necessarily mean more frequent use of narrow-spectrum antibiotics. The differences in each hospital’s ranking between DOT and DASC per 1000 DP ranged from −29.0% to 25.0%, respectively, with 27 hospitals (21.8%) having differences >10%. Conclusions We propose a novel composite metric for antibiotic stewardship, DASC, that combines consumption and spectrum as a potential replacement for DOT. Further studies are needed to evaluate whether benchmarking using the DASC will improve evaluations of stewardship.
科研通智能强力驱动
Strongly Powered by AbleSci AI